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ABSTRAK
Abstrak. Hipertensi menyebabkan perubahan dalam struktur dan fungsi cardial sebagai pemicu 
perubahan neurohormonal dan pembuluh darah pada hipertrofi jantung konsentris. Ekspansi 
volume miosit atau peningkatan tekanan akan memicu sintesis pra-proBrain Natriuretic 
Peptide (BNP) dalam miokardium ventrikel. Pre-proBNP akan dikonversi menjadi proBNP 
sedangkan proBNP akan dikonversi ke dalam bentuk BNP dan N-terminal proBNP (NTproBNP).
Tujuan. Penelitian ini bertujuan untuk mengetahui perbedaan BT pro BNP pada pasien hipertensi tanpa 
LVH dan pasien hipertensi dengan hipertrofi  ventrikel kiri. 
Metode. Desain penelitian adalah potong lintang di poliklinik kardiologi rawat jalan di Rumah 
Sakit Dr. Sardjito Yogyakarta dari bulan Agustus 2009 sampai jumlah sampel terpenuhi. Untuk 
menganalisis perbedaan antara dua kelompok pasien hipertensi menggunakan uji t-test untuk 
distribusi normal, sedangkan untuk distribusi normal dianalisis dengan uji Mann-Whitney 
U. Untuk menganalisis normalitas data dilakukan uji Kolmogorov-Smirnov. Perbedaan dua 
kelompok pasien hipertensi dianggap signifikan jika p < 0,005 dengan interval kepercayaan 95%.
Hasil. Hasil penelitian menunjukkan 73 subyek penelitian dikelompokkan menjadi 2 kelompok yaitu 
kelompok hipertensi tanpa LVH (31 subyek) dan dengan LVH (42 subyek) berdasarkan parameter 
ekokardiografi  (IVSD, LVPWd, LVIDd, LVM, dan LVMI) yang terdiri dari 24 laki-laki dan 49 perempuan. 
Karakteristik dasar antara kelompok hipertensi dengan dan tanpa LVH tidak berbeda secara signifi kan 
baik dalam usia, BMI, tekanan darah, durasi karakteristik terapi hipertensi dari penggunaan obat-obatan 
seperti ACEI, ARB, β-blocker, CCB, spironolactone dan furosemide. Rerata tingkat NT proBNP pada 
kelompok hipertensi tanpa LVH (46,60±45,51) dan hipertensi dengan kelompok hipertrofi  ventrikel kiri 
(201,60 ±192,30 ng/ml). Dari hasil uji Kolmogrov-Smirnov hasil bahwa distribusi data tidak normal 
sehingga digunakan uji Mann-Whitney U, memperoleh perbedaan yang signifikan secara statistik.
Kesimpulan. Ada perbedaan yang signifi kan dalam tingkat rata-rata serum NT proBNP pada pasien 
hipertensi tanpa LVH dan pasien hipertensi dengan hipertrofi  ventrikel kiri.




World Health Organization (WHO) 
reported that the systolic blood pressure 
> 115 mmHg is responsible for 62% of  
cerebrovascular disease and 49% of  ischemic 
heart disease with slight variations infl uenced 
by gender. In the end that is not optimal 
blood pressure is a risk factor for all-cause 
mortality in the world.1
The prevalence of  hypertension in 
Indonesia in 2007 was 32.2%, and the highest 
prevalence was found in the province of  South 
Kalimantan (39.6%), the lowest in West Papua 
(20.1%). Socio-demographic factors were 
found at risk for hypertension were age, gender, 
education and employment, behavioral risk 
factors are at risk for hypertension is first 
ever smoking, alcohol consumption one last 
month, one time consumption of  caffeinated 
beverages per day, and less physical activity, 
risk factors physical risk for hypertension is 
obesity and obesity abdominal.2
Essential hypertension is a major risk 
factor for cardiovascular disease. Terminal 
kidney disease incidence and prevalence of  
heart failure also increases with the presence 
of  hypertension and blood pressure control 
is not adequate.3,4,5
One of  complications of  hypertension 
is the occurrence of  ventricular hypertrophy 
in the left (Left Ventricular Hypertrophy). 
Left ventricular hypertrophy is marked by 
hypertrophy concentric with hypertrophy 
circumferential miofi bril, contractility which 
increased, an increase in thickness of  wall 
ABSTRACT
Introduction. Hypertension cause changes in the structure and function of  cardial as triggers 
neurohormonal and vascular changes that concentric cardiac hypertrophy. Myocyte volume expansion or 
increased pressure will trigger the synthesis of  pre-proBrain Natriuretic Peptide (BNP) in the ventricular 
myocardium. Pre-proBNP will be converted into proBNP and proBNP will be converted into the form 
of  BNP and N-terminal proBNP (NT proBNP).
Aim. This study aimed to determine differences in BT pro BNP in hypertensive patients without LVH and 
hypertensive patients with LVH. The study design was cross-sectional in cardiology polyclinic`s outpatient 
at Dr. Sardjito General Hospital Yogyakarta from August 2009 until the sample number is fulfi lled. 
Method. To analyze the difference between the two groups of  hypertensive patients using the t-test for 
normal distribution, while for abnormal distribution were analyzed with the Mann-Whitney U test. To 
analyze the normality of  data conducted by Kolmogorov-Smirnov. The differences of  two groups of  
hypertensive patients considered as signifi cant if  p < 0.005 with confi dence interval of  95%.
Results. The results showed 73 study subjects grouped subjects into 2 groups: hypertensive subjects without 
LVH (31 subjects) and with LVH (42 subjects) based on echocardiography parameters (IVSD, LVPWd, 
LVIDd, LVM, and LVMI) consisting of  24 males and 49 females. The baseline characteristics between the 
study groups of  hypertensive subjects with and without LVH did not differ signifi cantly either in age, 
BMI, blood pressure, duration of  hypertention therapeutic characteristics of  the use of  drugs such as 
ACEI, ARB, β-blocker, CCB, spironolactone and furosemide. Mean NT proBNP levels in hypertensive 
group without LVH (46.60 ± 45.51) and hypertention with LVH group (201.60 ±192.30 ng/ml). From 
the results of  the Kolmogrov-Smirnov test result that the data distribution was not normal then used 
Mann-Whitney U test, obtained a statistically signifi cant differences.
Conclusion. There were signifi cant differences in the mean levels of  serum NT proBNP in hypertensive 
patients without LVH and hypertensive patients with LVH.
Keywords:  hypertension,  left ventricular hypertrophy (LVH),  N-terminal proBrain natriuretic Peptide
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ventricular, volume at the end of  diastolic 
are low, and disturbances relaxation (diastolic 
dysfunction). On 30-50% individuals with 
hypertension degrees I and II have left 
ventricular relaxation disorders, and on 
hypertension with degrees who more heavier, 
2/3 of  patients had abnormal relaxation left 
ventricular.1,6 Expansion volume or pressure 
myocytes which increased, resulted in the 
stretch on ventricular wall so that triggering 
synthesis of  pre-proBrain Natriuretic Peptide 
(BNP) in myocardium ventricle. Pre-proBNP 
will later be converted into proBNP and 
proBNP will converted into form of  BNP 
and N-terminal proBNP (NT proBNP). 
The release of  BNP and NT proBNP will 
fi x the relaxation myocardium and have an 
important role in the responding an acute 
increase volume ventricular with counteract 
the effects vasoconstriction, retention, and 
effects antidiuresis from system renin-
angiotensin which activated.7,8,9,10
LITERATURE REVIEW
Myocyte hypertrophy is a compensatory 
response of  increased afterload. Mechanical 
and neurohor monal  st imulat ion that 
accompany hypertension may activate 
myocardial cell growth, gene expression and 
subsequently left ventricular hypertrophy. 
Activation of  the renin angiotensin system 
causes the growth of  cells and interstitial 
matrix components, so that LVH is caused by 
myocyte hypertrophy and myocyte imbalance 
between myocardial interstitial skeletal 
structure. Two major factors that trigger 
hypertrophy is a biomechanical stress and 
neurohumoral factors. According to the law 
of  Laplace, afterload induced increase in 
systolic wall stress which offset an increase in 
thickness of  the ventricular wall of  the heart. 
Ion channels that are sensitive to the plasma 
membrane indicated strain kardial myocytes. 
The myocyte stretch induces the synthesis and 
secretion of  several growth factors including 
insulin-like growth factor-I, angiotensin II and 
endothelin I, and humoral factors is suffi cient 
to induce myocyte hypertrophy. Humoral 
factors such as angiotensin II, aldosterone, 
noradrenaline and endothelin directly induce 
hypertrophy and status associated with 
maladaptive processes to increase myocardial 
fi brosis in ventricular hypertrophy.4
Remodeling is a change in the structure 
(dimensions, mass, shape) and function of  the 
heart (called remodeling cardiac or ventricular) 
as a result of  hemodynamic load and cardiac 
or injury associated with neurohormonal 
activation. Remodeling is often divided into 
physiological or pathological or classified 
adaptive and maladaptive.4
 Remodeling associated with cellular 
changes including myocyte hypertrophy, 
myocyte loss due to apoptosis or necrosis and 
fi broblast proliferation and fi brosis. Although 
the pathways and cellular involvement in 
LV remodeling are not fully understood, the 
molecular mechanisms at the level of  the strain 
is myocytes, there is increased production or 
release of  angiotensin II, norepinephrine 
and endothelin, stimulates neurohormonal 
changes in protein expression and myocyte 
hypertrophy, increased angiotensin II, 
aldosterone and stimulates cytokine synthesis 
of  collagen, causing fi brosis and extracellular 
matrix remodeling. Reduction of  nitric 
oxide bioactivity effect on cell growth 
and interstitial, at normal levels inhibit 
remodeling. The end result of  this research is 
a pathological remodeling of  cardiac damage 
and increased neurohormonal activation. 
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Remodeling and myocardial changes play 
a role in the pathogenesis of  ventricular 
arrhythmias.10
There are 3 major groups natriuretic 
peptide, namely atrial natriuretic peptide 
(ANP), B-type natriuretic peptide (BNP), and 
C-type natriuretic peptide (CNP). Natriuretic 
peptide is the characteristic biochemical 
structure that consists of  17 amino acid ring 
and a disulfi de bond between two cysteine 
molecules. B-type natriuretic peptide is also 
called brain-type natriuretic peptide, is fi rst 
discovered in 1988 after isolated from pig 
brain. Soon after the discovery, the BNP is a 
cardiac hormone that comes from the heart.7,8
Atrial natriuretic peptide (ANP) and 
B-type natriuretic peptide (BNP) is known as 
an antagonist of  the renin-angiotensin system. 
C-type natriuretic peptide (CNP) is a new 
member of  natriuretic peptide group but the 
difference of  the main source in the vascular 
endothelium. Unlike ANP and BNP, CNP 
does not have direct natriuretic activity. This 
is because CNP is a selective agonist for the 
B-type natriuretic receptor whereas ANP and 
BNP are selective for the A-type natriuretic 
receptor.8
Major stimulus for the release of  
BNP is increased myocardial stress due 
to increase volume or pressure, increased 
efforts mechanical (mechanical effort), 
neurohormonal factors such as endothelin, 
angiotensin II, adrenal steroids, infl ammatory 
cytokines, growth factors, prostaglandins, 
thyroid hormone, and alpha-adrenergic 
agents. Although the release of  BNP occurs 
under normal circumstances, increased 
regulation could occur in a state of  volume 
overload.15
METHODS
This study was a cross-sectional study 
were performed at the Cardiology outpatient 
Dr. Sardjito General Hospital Yogyakarta and 
Clinical Pathology Laboratory Dr. Sardjito 
Yogyakarta. The study began in August 2009.
The study population was patients 
attending Cardiology outpatient Dr. Sardjito 
General Hospital Yogyakarta. As the sample 
was hypertensive patients at the Cardiology 
outpatient dr. Sardjito General Hospital 
Yogyakarta diagnosed by JNC VII criteria. 
Study subjects were recruited by consecutive 
sampling method.
Inclusion criteria for the study were 
all hypertensive patients who have been 
diagnosed based on the criterias of  JNC 
VII 2003, in the treatment of  hypertensive 
patients, stated were willing to participate 
in this study and signed a letter of  informed 
consent or informed consent of  research 
subjects as well as both medical measures 
blood sampling.
Exclusion criteria included acute 
coronary syndrome, primary valvular heart 
disease, permanent arrhythmia, obesity, 
diabetes mellitus, chronic renal disease, 
hyperthyroidism, anemia, and stroke.
Estimates of  the 24 samples in each group 
were considered adequate to detect differences 
in levels of  NT-proBNP in hypertension with 
left ventricular hypertrophy and without left 
ventricular hypertrophy. Data presented in 
the form of  mean and standard deviations 
(mean ± standard deviation). The difference 
between the mean values of  continuous data 
were analyzed with the unpaired Student t-test 
for normal distribution, while the distribution 
was not normal was analyzed by the Mann-
The Journal of  Internal Medicine, Acta Interna, Volume 5, Number 1, June 2015: 1-8
5 
Table  1.  Basic Characteristics of  subject
Variabel With left ventricle hypertrophy n = 42
Without left ventricle hypertrophy 
n = 31 P
Age (years) 50.70 ± 11.40 59.80 ± 12.20 0.7
Sex 0.8
Male     n (%) 13 (31.00) 11 (35.50)
Female n (%) 29 (69.00) 20 (64.50)
IMT  kg/m2 25.00 ± 3.16 24.30 ± 3.40 0.3
TDS mmHg 145.00 ± 18.20 145.00 ± 14.20 0.9
TDD mmHg 88.00 ± 10.40 88.00 ± 8.40 0.9
HR  x/mnt 76.70 ± 10.80 76.10 ± 5.50 0.7
Hypertension 0.7
Stage I n (%) 40 (55.60%) 33 (44.40%)
Stage II n (%) 47 (65.00%) 26 (35.00%)
Long suffered (years) 9.50 ± 6.90 8.50 ± 6.70 0.5
Table 2. Therapy characteristics of  subject
Variable With left ventricle Hypertrophy n = 42
Without  left ventricle hypertrophy 
n = 31 P
ACEI n (%) 24 (57.10) 12 (38.70) 0.1
ARB n (%) 11 (26.20) 13 (41.90) 0.2
Β-Blocker n (%) 9 (21.40) 5 (17.20) 0.7
CCB  n (%) 9 (21.40) 7 (24.10) 0.7
Furosemid n (%) 26 (61.90) 10 (31.00) 0.1
Spironolactone n (%) 4 (9.5) 1 (3.4) 0.6
Drug use
Without drug (%) 8.00 10.00
1 drug (%) 64.00 60.00 0.98
2 drug (%) 20.00 20.00
3 drug (%) 8.00 1000
Maulana et al.
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Whitney U test. Categorical data discrepancies 
with Chi Square test. Data were presented with 
95% confi dence interval and P value> 0.05 was 
statistically signifi cant.
RESULT AND DISCUSSION
Obtained 73 subjects with hypertension 
without left ventricular hypertrophy (31 
subjects) and hypertension with left ventricular 
hypertrophy (42 subjects). Study subjects 
consisted of  24 (32.87%) men and 49 (67.13%) 
were women.
Figure 1 i s a table showing the suitability 
2x2 echocardiography examination by 2 
examiners. From the above calculation kappa 
value of  0.69 is obtained, which means the 
power of  inter-observer agreement (inter-
examiner) is quite high (satisfactory or good 
category). 
Table 3 shows the parameters used in 
measuring left ventricular hypertrophy in 
subjects research.
Age factor does not affect the outcome 
of  the study between the two groups. Role in 
the life of  considerable geometric changes and 
left ventricular mass, especially in patients 
with essential hypertension often occurs in 
the elderly, male gender, hypertension is severe 
degrees of  hypertension, has been suffering 
from hypertension more than a year, in obese 
patients and patients with DM.11 
Gender factor has no effect in this 
study because it was not found significant 
differences (p=0.8). Women will be better 
protected from cardiovascular disease and 
hypertension due to differences in estrogen 
and androgen hormone balance and also 
associated with the RAS system primarily 
AT2 receptor is expressed lower in male rats 
that facilitate the occurrence of  cardiovascular 
disease and hypertension.12  But in this study 
the age range most fall into menopause age.
Relationship of  obesity and hypertension 
complex, multifactorial mechanisms including 
activation of  the sympathetic system and 
renin, insulin resistance, abnormal renal 
Table 3. Parameters used in measuring left ventricular hypertrophy
Variable With left ventricle hypertrophyn = 42
Without left ventricle hypertrophy 
n = 31 P
EF % (Mean±SD) 65.50 ± 8.00 67.7 ± 6.30 0.2
IVSD mm (Mean±SD) 1.30 ± 0.20 1.0 ± 0.10 0.00
LVPWd mm(Mean±SD) 1.20 ± 0.10 1.0 ± 0.10 0.00
LVIDd mm (Mean±SD) 4.7 ± 0.50 4.3 ± 0.30 0.02
LVM g/m2 (Mean±SD) 250.50 ± 74.10 160.20 ± 27.00 0.00
LVMI g/m2(Mean±SD) 155.10 ± 40.70 100.0 ± 13.0 0.00
Table 4.  Differences of  level NT proBNP





NT proBNP (pg/ml) 201.60 ± 192.30 46.6 ± 45.10 0.00 *
Exp :  * Mann Whitney U test, signifi cant if  p < 0.05.
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sodium regulation, and the possibility of  
leptin resistance and natriuretic peptides.
Data from systolic and diastolic blood 
pressure in both groups subjects not found a 
signifi cant difference (p=0.9) so that it can be 
concluded that the effect of  high blood pressure 
on the outcome of  research that NT proBNP 
was similar in both groups of  subjects.
Long suffered from hypertension between 
the two groups were similar in this study. In 
another study concluded that long hypertension 
associated with left ventricular hypertrophy (p 
<0.001) so that the length of  suffering from 
hypertension is a strong predictor of  the 
occurrence of  left ventricular hypertrophy.13
Use of  ACEI and ARB are very infl uential 
on the fi nal outcome because both drugs have 
anti remodeling induced heart muscle due to the 
blockade of  RAS-related effects of  angiotensin II 
on blood pressure, and systemic hemodynamic 
and infl ammatory markers cardial.5
The use of  spironolactone is also 
quite important because there is a study 
of  the role of  left ventricular hypertrophy 
regression. Hyperaldosteronism can increase 
the incidence of  resistant hypertension 
thereby increasing blood pressure induced 
left ventricular hypertrophy. Spironolactone 
is a mineralocorticoid receptor antagonist 
can control blood pressure and reduce left 
ventricular hypertrophy, but in this study 
received spironolactone 25-50 mg daily with 
optimal doses of  thiazide diuretics.14 
The use of  beta blockers, CCB, and 
furosemide also do not have a significant 
difference so it can be concluded that all these 
drugs do not affect the fi nal outcome of  this 
study. The fi nal results of  this study showed 
that consistent with the hypothesis that there 
is a statistically signifi cant difference using the 
Mann-Whitney test mean NT proBNP levels 
between the two groups of  subjects (p=0.00). 
Kolmogorov-Smirnov test showed that the 
data distribution is not normal. The results 
obtained from the some of  the data from the 
hypertensive with left ventricular hypertrophy 
with NT proBNP levels in a number of  
normal and hypertensive group without left 
ventricular hypertrophy who have high levels 
of  NT proBNP.
The weakness in this study is a research 
method that is cross-sectional so it has 
limitations in determining the levels of  NT 
proBNP correlation with hypertension and 
left ventricular hypertrophy.
CONCLUSION
There were signifi cant differences in levels 
of  N-terminal proBrain Natriuretic Peptide 
(NT proBNP) in hypertensive patients without 
left ventricular hypertrophy and hypertensive 
patients with left ventricular hypertrophy.
Need to do more research on the 
N-terminal proBrain Natriuretic Peptide (NT 
proBNP) with left ventricular hypertrophy 
so it can be determined the cut-off  point for 
the detection of  left ventricular hypertrophy.
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